We enter into a licensing agreement with Vertex Pharmaceuticals for four promising R&D DDR programs. The addition of the DDR portfolio in-licensed from Vertex to our own in-house DDR platform has positioned us as one of the key players in the DDR field.
We want to use the advanced data analytics capabilities of the U.S. company Palantir to more rapidly develop and deliver medicines and commercialize new products. This could also play a part in the development of entirely new therapeutic options for patients in the future. Initially, we will use Palantir’s technology in cancer treatment and patient services. Later on it can be used in other areas of the company.
The U.S. Food and Drug Administration (FDA) grants the first approval of an oncology treatment for metastatic Merkel cell carcinoma.
Less than two months later, the FDA grants the next approval for Bavencio® – for the treatment of patients with advanced or metastatic urothelial cancer.
We open an applications laboratory in China through which we provide comprehensive, customized services for our quality products. This also effectively allows us to seek and foster creative collaboration with customers for new applications and formulations.
The European Patent Office grants us the patent for our CRISPR technology used in a genomic integration method for eukaryotic cells. We were awarded similar patents by the Australian, Canadian and Singapore patent offices over the course of 2017.
Mavenclad® (cladribine tablets) is approved for MS patients in the EU, and is the first oral short-course treatment for highly active relapsing multiple sclerosis.
At the first Seoul Biennale of Architecture and Urbanism, together with our collaboration partners OLEDWorks, OPVIUS and Kolon, we present a new textile façade concept combining OPV (organic photovoltaics) and OLED (organic light-emitting diode) technologies.
The closing of the Biosimilars sale to Fresenius announced on September 1 is in line with our strategy to focus our Healthcare business sector on the pipeline of innovative medicines in oncology, immuno-oncology and immunology. We receive an upfront payment of € 156 million and are entitled to milestone payments of up to € 500 million, plus royalties on future product sales.
We are currently preparing strategic options for Consumer Health. These include both a full or partial sale of the business as well as strategic partnerships. We are thus focusing on our innovation-driven Biopharma pipeline and are initiating the next stage of the successful further development of the Consumer Health business.
We exhibit at Europe’s most important motor show with our own stand for the first time. Our presentation centers on high-tech materials for lighting, antennas, displays and surfaces.
The European Commission approves our oncology medicine Bavencio® in this rare and aggressive form of skin cancer.
We open a new Life Science Center in Burlington, north of Boston, to strengthen our presence in this key global science region. The new facility serves as a regional hub for scientific advances and customer collaboration. The Greater Boston area is a hotbed of life science innovation.
We open our new production facility for liquid crystal window modules in Veldhoven, a town near Eindhoven. With an investment of around € 15 million, we are continuing to build on our expertise as the market and technology leader in liquid crystals for displays by moving into other applications beyond televisions, laptops, smartphones, and tablet PCs.
1668 Friedrich Jacob Merck purchases a pharmacy in Darmstadt.
1754 Johann Justus Merck works during his training in Stuttgart with the “Pharmacopoea Wirtenbergica”, the most modern pharmaceutical formulary of its time.
1827 Emanuel Merck drives the transformation from a pharmacy craft to a research-based industrial company forward with the presentation of the “Novitäten Cabinet”, the cabinet of novelties.
1850 In order to ensure the continued existence of his company, Emanuel Merck establishes the partnership E. Merck KG, Darmstadt, Germany, together with his sons.
1879 Our company develops internationally, establishing business contacts to Asia (1832), North America (1845), South America (1851), Africa (1867), and Australia (1879).
1904 The entire factory is moved to its present-day location on Frankfurter Strasse and is expanded.
1917 The U.S. subsidiary Merck & Co., Inc., headquartered in New Jersey, USA, is expropriated and is entirely legally and economically independent today. Outside the United States and Canada, the company operates as MSD.
1987 Immunology research starts at Merck KGaA, Darmstadt, Germany, with a focus on cancer therapy.
1995 Establishment of Merck KGaA, Darmstadt, Germany. With a volume of DM 2.4 billion, this represents the largest public offering in German history at that time.
2007 The acquisition of Serono succeeds, making us a leading biotech company.
2010 The acquisition of Millipore in the United States creates a leading global partner for the life science industry.
2015 With the acquisition of the U.S. company Sigma-Aldrich, our company further expands its leading position in the life science business. The portfolio now encompasses more than 300,000 products.
2018 We celebrate our anniversary.